• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • EoE Learning Hub
    • Bullous Pemphigoid Learning Hub
    • Chronic Spontaneous Urticaria Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
    • Type 2 Asthma Learning Hub
    • Prurigo Nodularis Learning Hub
    • Atopic Dermatitis Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region

Educational Resources

Categories
Dermatology: 
  • Atopic dermatitis
  • Bullous pemphigoid
  • Chronic spontaneous urticaria
  • Prurigo nodularis
Gastroenterology: 
  • Eosinophilic esophagitis
Pulmonology: 
  • Asthma
  • Chronic obstructive pulmonary disease
Rhinology: 
  • Chronic rhinosinusitis with nasal polyps
Filters
Topic: 
  • Burden of disease
  • Pathophysiology
  • Guidelines and recommendations
  • Clinical management
  • Co-existing type 2 inflammatory diseases
Format: 
  • Expert Video
  • Podcast
  • Slide presentation
  • Infographic
  • Video animation
  • Interactivity
Length: 
  • Short (<5 minutes)
  • Medium (5-15 minutes)
  • Long (> 15 minutes)
Sort by: Newest
  • Newest
  • Oldest
  • A-Z
  • Z-A
Beyond Itch: The Multifaceted Role of IL-4/IL-13 in the Pathogenesis of PN
Dermatology
7 min
expert video

Beyond Itch: The Multifaceted Role of IL-4/IL-13 in the Pathogenesis of PN

The Shared Path: Type 2 Inflammation As a Driver of Chronic Itch
Dermatology
11 min
expert video

The Shared Path: Type 2 Inflammation As a Driver of Chronic Itch

Understanding the Contribution of IL-4 in the Development of Fibrosis in Prurigo Nodularis
Dermatology
2 min
expert video

Understanding the Contribution of IL-4 in the Development of Fibrosis in Prurigo Nodularis

Beyond the Visible: The Cumulative Burden of Prurigo Nodularis
Dermatology
2 min
expert video

Beyond the Visible: The Cumulative Burden of Prurigo Nodularis

Beyond the Skin: Understanding Systemic Comorbidities in Prurigo Nodularis
Dermatology
2 min
expert video

Beyond the Skin: Understanding Systemic Comorbidities in Prurigo Nodularis

Understanding the Full Scope of PN: Lesions, Dyspigmentation, and Patient Burden
Dermatology
2 min
expert video

Understanding the Full Scope of PN: Lesions, Dyspigmentation, and Patient Burden

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
Dermatology
3 min
expert video

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

On the Surface: Restoring the Skin Barrier in Patients with AD
Dermatology
2 min
expert video

On the Surface: Restoring the Skin Barrier in Patients with AD

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
Dermatology
3 min
expert video

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
Dermatology
3 min
expert video

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
Dermatology
5 min
expert video

Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities

Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
Dermatology
4 min
expert video

Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment

    1234
    ...
    21